Key result
Familial hypercholesterolemia mutation carriers with LDL ≥/dl had a 22-fold increased risk of CAD compared to individuals with LDL </dl and no mutation.
Why the study?
The prevalence of familial hypercholesterolemia mutations among individuals with severe hypercholesterolemia and the variation in CAD risk by mutation status beyond LDL cholesterol levels were unclear.
Does the presence of a familial hypercholesterolemia mutation increase the risk of CAD beyond the observed LDL cholesterol level in patients with severe hypercholesterolemia?
Observational (n=26,025)
Yes
Does the presence of a familial hypercholesterolemia mutation increase the risk of CAD beyond the observed LDL cholesterol level in patients with severe hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
Although FH mutations are identified in <2% of individuals with severe hypercholesterolemia, mutation carriers face a substantially higher risk of CAD compared to non-carriers with similar LDL cholesterol levels.
About 7% of US adults have severe hypercholesterolemia (untreated LDL cholesterol ≥190 mg/dl). Such high LDL levels may be due to familial hypercholesterolemia (FH), a condition caused by a single mutation in any of three genes. Lifelong elevations in LDL cholesterol in FH mutation carriers may confer CAD risk beyond that captured by a single LDL cholesterol measurement. Assess the prevalence of a FH mutation among those with severe hypercholesterolemia and determine whether CAD risk varies according to mutation status beyond the observed LDL cholesterol. Three genes causative for FH ( LDLR , APOB , PCSK9 ) were sequenced in 26,025 participants from 7 case-control studies (5,540 CAD cases, 8,577 CAD-free controls) and 5 prospective cohort studies (11,908 participants). FH mutations included loss-of-function variants in LDLR , missense mutations in LDLR predicted to be damaging, and variants linked to FH in ClinVar, a clinical genetics database. Among 8,577 CAD-free control participants, 430 had LDL cholesterol ≥190 mg/dl; of these, only eight (1.9%) carried a FH mutation. Similarly, among 11,908 participants from 5 prospective cohorts, 956 had LDL cholesterol ≥190 mg/dl and of these, only 16 (1.7%) carried a FH mutation. Within any stratum of observed LDL cholesterol, risk of CAD was higher among FH mutation carriers when compared with non-carriers. When compared to a reference group with LDL cholesterol <130 mg/dl and no mutation, participants with LDL cholesterol ≥190 mg/dl and no FH mutation had six-fold higher risk for CAD (OR 6.0; 95%CI 5.2–6.9) whereas those with LDL cholesterol ≥190 mg/dl as well as a FH mutation demonstrated twenty-two fold increased risk (OR 22.3; 95%CI 10.7–53.2). Among individuals with LDL cholesterol ≥190 mg/dl, gene sequencing identified a FH mutation in <2%. However, for any given observed LDL cholesterol, FH mutation carriers are at substantially increased risk for CAD.
No takes yet. Share an insight, caveat, or question.
Khera et al. (2016) conducted an observational in Severe hypercholesterolemia (n=26,025). Familial hypercholesterolemia mutation with LDL ≥190 mg/dl vs. No mutation with LDL <130 mg/dl was evaluated on Coronary artery disease (OR 22.3, 95% CI 10.7-53.2). Familial hypercholesterolemia mutation carriers with LDL ≥/dl had a 22-fold increased risk of CAD compared to individuals with LDL </dl and no mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: